Join
Live feed
·
PRReleasevia Quantisnow
Gilead Sciences Inc. logo

Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta

ByQuantisnow·Wall Street's wire, on your screen.
GILD· Gilead Sciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GILD (Gilead Sciences Inc.) and more on Quantisnow.